tbuckley/cabot-search huggingface dataset:
AB1274 ADULT-ONSET STILL’S DISEASE IN WESTERN AUSTRALIA: EPIDEMIOLOGY, COMORBIDITY AND LONG-TERM OUTCOME.
Authors: J. Nossent, W. Raymond, H. Keen, D. Preen, C. Inderjeeth
Journal: Annals of the Rheumatic Diseases (2022)

Background Adult-onset Stills disease (AOSD) is a rare, potentially life-threatening autoinflammatory condition for which the reported prevalence shows regional variation and where comparative long-term outcome data are scarce (1). Objectives To investigate annual incidence and point prevalence of AOSD in Western Australia (WA) and compare long-term health-related outcomes between AOSD patients and hospital-based controls. Methods Population-based cohort study using longitudinally linked administrative health data from all hospitals in WA between 1999 and 2013. ASD patients (ICD-10-AM code M06.1) were matched to controls for age and gender. Rate and odds ratios (RR/OR) with 95% confidence intervals (CI) were used to compare ASD patients and controls for serious infections (SI), osteoporosis, joint replacement and the modified Charlson Comorbidity (mCCI). Results In total 52 patients had incident AOSD for an average period incidence of 0.22/100,000 and a point prevalence of 2.4 /100.000 (per 30/12/2013). Compared to controls, ASD patients (median age 41.5 years, 59.6% females) had higher odds of prior liver disease (OR 2.67, 95%CI: 1.31-5.45), fever (OR 54.1, 95%CI: 6.6-43), rash (OR 15.7, 95%CI: 4.08-60.8) and SI (OR 4.36, 95%CI: 2.11-22.8). During 49 months of follow up, crude mortality (11.5% vs 7.5%; p=0.34), survival at one and five years (p=0.78) and m-CCI score at last observation (median 2 vs 2) were similar for ASD patients and controls. However, the odds for subsequent joint replacement (in 7 patients; 13.5%) (OR 45.5, 95%CI: 4.57-93), osteoporosis (OR 31.3, 95%CI: 3.43-97) and SI (RR 5.68, 95%CI: 6.61-8.74) were significantly higher in ASD patients. Conclusion The epidemiology and demographics of AOSD in Western Australia fall within the internationally reported range. Compared to controls, AOSD patients presented higher rates of liver disease, rash and SI before disease onset. Mortality following AOSD was not increased for five years despite high rates of chronic arthritis requiring joint replacement, SI, and osteoporosis. References [1]Tomaras, S.; Goetzke, C.C.; Kallinich, T.; Feist, E. Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach. J. Clin. Med. 2021, 10 , 733. Acknowledgements Supported by a grant from the Arthritis Foundation of Western Australia Disclosure of Interests None declared
AB1026 ASSOCIATION BETWEEN TRABECULAR BONE SCORE, 10-YEAR PROBABILITY RISK FOR FRACTURE, AND VERTEBRAL FRACTURES IN RHEUMATOID ARTHRITIS
Authors: H. Boutaibi, H. Azzouzi, F. Chennouf, I. Linda
Journal: Annals of the Rheumatic Diseases (2022)

Background Trabecular bone score (TBS) utility in vertebral fracture prediction is still questionable. Objectives To evaluate the association of trabecular bone score (TBS), the fracture risk assessment tool (FRAX), and TBS adjusted FRAX with prevalent vertebral fractures (VFs) in Rheumatoid Arthritis (RA). Methods This is a cross-sectional study of RA patients diagnosed according to ACR/EULAR 2010 criteria and recruited in our rheumatology department. Patients with an age under 40 or above 90, diabetes, thyroid disease, hyperparathyroidism, cancer, cirrhosis, renal clearance &lt; 70 mL/min, and those using osteoporosis drugs or having a body mass index (BMI) of more than 36kg/m 2 were excluded. TBS, bone mineral density (BMD), and vertebral fracture assessment (VFA) were obtained using dual-energy X-ray absorptiometry (DXA). We used the FRAX tool to assess the 10-year probability of major osteoporotic fracture (MOF-FRAX) and hip fracture (HF-FRAX) with and without BMD. These parameters were further adjusted for TBS (FRAX/TBS-MOF and FRAX/TBS-HF). Prevalent VF was evaluated by two readers using VFA. We defined patients with prevalent VFs as patients who had moderate-to-severe degree VFs of the thoracic and lumbar spine (T4 to L4) according to Genant criteria. Osteoporosis was defined as a T-score &lt; -2.5 in the lumbar spine, femoral neck, or 1/3 of the non-dominant forearm location. Clinical data, results of radiological and laboratory tests performed on the same day of the DXA scan were collected. Receiver operating characteristic curves were generated by SPSS.20 to study the predictability of each parameter for VF. Results Sixty-nine patients were enrolled, and 66.7% of them were menopausal. Their mean lumbar spine, hip, and forearm BMD were 0.817 ± 0.155, 0.681 ± 0.676, and 0.572 ± 0.119, respectively. The mean TBS was 1.328 ± 1.041. Thirty-nine patients (56.5 %) had osteoporosis. Nine patients (13%) had moderate to severe VFs with predominance at the thoracic spine (77.8%). There was a negative correlation between MOF-FRAX score and lumbar spine BMD (r = -0.473; p &lt; 0.001), and also hip BMD (r = - 0.530; p &lt; 0.001), while there was no correlation between MOF-FRAX score, HF-FRAX and TBS. The areas under curves were 0.824, 0.800, 0.792, and 0.443 for the FRAX-MOF score with BMD, FRAX-MOF score, FRAX-MOF score adjusted for TBS, and TBS, respectively. Conclusion In this study, MOF-FRAX score showed a better correlation with BMD than TBS. It was also superior to TBS and TBS adjusted FRAX in identifying prevalent VFs in RA patients. Disclosure of Interests None declared
POS1109 GENETIC MARKERS PREDICT THE DEVELOPMENT OF POSTOPERATIVE PAIN
Authors: V. Nesterenko, A. Karateev, M. Makarov, E. Bialik, S. Makarov, A. Lila, V. Bialik, S. Glukhova, M. Nurmukhametov, V. Kuznecov, N. Burikov, A. Roskidailo
Journal: Annals of the Rheumatic Diseases (2022)

Background Postoperative pain (POP) is a serious complication that affects the outcome of total arthroplasty (TA) of the knee (CJ) and hip (HJ) joints in patients with osteoarthritis (OA). The search for the genetic characteristics of POP is an urgent direction in the study of this problem. Objectives To determine the relationship between the polymorphisms of the KCNS1, COMT, and OPRM1 genes and the development of postoperative pain in patients with osteoarthritis of the knee joint and hip joint who underwent total arthroplasty. Methods The study group consisted of 95 patients with knee osteoarthritis and / or hip joint osteoarthritis (64.6% of women; mean age - 65.4 ± 9.0 years) who underwent TA CJ (47.8%) or TA HJ (52.2 %). The presence of POP was determined when it persisted or appeared after 3 and 6 months. After surgery, pain in the area of the operated joint ≥40 mm by 100 mm visual analogue scale. All patients underwent genotyping of KCNS1 (rs734784), COMT (rs6269, rs4633), and OPRM1 (rs1799971) gene polymorphisms by real-time polymerase chain reaction using original sequence-specific primers and probes labeled with various fluorescent labels. Registration and interpretation of the obtained results were carried out on a DT-96 amplifier (DNA-Technology LLC, Russia). Results POP was observed in 32.6% of patients who underwent TA CJ or TA HJ. The incidence of POP after TA CJ and TA HJ was 30.2% and 34.0%, respectively (p = 0.882). There were no differences in the frequencies of genotypes of the studied genes (p&gt;0.05). The presence of the homozygous GG genotype of the KCNS1 gene polymorphism (rs734784) was associated with the presence of POP in accordance with the recessive genetic model (GG vs AA + AG; odds ratio (OR) - 3.96 [95% confidence interval (CI): 1, 51; 10.37]; p = 0.005). The presence in the genotype of the mutant allele T (TT + CT) of the COMT polymorphism (rs4633) reduced the risk of developing POP compared with the carriage of the CC genotype (OR = 0.32 [95% CI: 0.12; 0.83]; p = 0, 02) according to the dominant genetic model. There was no statistically significant correlation between the development of POP and the carriage of various genotypes and alleles of the COMT (rs6269) and OPRM1 (rs1799971) genes. Conclusion There is a statistically significant association between the polymorphism of the KCNS1 (rs734784) and COMT (rs4633) genes and the development of chronic POP in patients who underwent TA CJ and TA HJ. Further studies of the genetic predisposition to POP are required using more clinical material. Disclosure of Interests None declared
AB0164 ARE PATIENTS WITH RA IN REMISSION IN FINLAND DURING THE COVID TIMES? RESULTS FROM THE FINNISH QUALITY REGISTER
Authors: L. Weman, J. Kärki, J. Huhtakangas, J. Rutanen, L. Kuusalo, H. Salo, T. Sokka-Isler
Journal: Annals of the Rheumatic Diseases (2022)

Background Worries have been expressed, concerning the care of chronic diseases during the Covid times (1). Objectives To study the current status of patients with RA in the Finnish quality register database. Methods Patients who receive care for RA were identified in the database. Clinical and demographic data from the last visits during 2020-21 were collected, including swollen (SJC46) and tender joint counts (TJC46), doctor assessment of disease activity (Dr global), laboratory tests for inflammatory and serology markers, patient reported outcomes (PROs), and DAS28. Regression models were applied to compare measures of clinical status between the health care regions, adjusted for gender, age, ACPA status, and disease duration. Results A total of 14163 patients (72% female, mean (SD) age 62 (14) years, median (IQR) disease duration 8.5 (2.6, 20) years, 84% ACPA positive) were identified. For the entire population, the median (IQR) SJC46 was 0 (0, 1), TJC46 0 (0, 2), ESR 8 (5, 18), CRP 3 (1, 6), and dr global 8 (0, 19). Among PROs, median (IQR) HAQ was 0.5 (0, 1), pain 26 (10, 51), fatigue 28 (8, 54) and patient global 29 (11, 51). Between health care regions, statistically significant differences were found for all variables due to a large sample size. The mean (SD) DAS28 was 2.3 (0.9) for the entire group and 69 % of all patients had DAS28&lt;2.6. The median DAS28 ranged from 2 to 2.7 among health care regions (Figure 1) (p&lt;0.001). Majority of patients were taking csDMARDs only. Figure 1. Rheumatoid arthritis in 2020-21: The median DAS28-values in 19 regions in Finland. Conclusion The quality register provides comprehensive real-world data on the current status of patients with RA. A majority of patients can be considered being in remission even during the Covid times. References [1] Glintborg et al. Rheumatology (Oxford) 2021 Oct 9;60(SI):SI3-SI12 Acknowledgements I would like to thank The Finnish Society for Rheumatology and The Finnish Psoriasis Association for their grants. Disclosure of Interests None declared
AB1292 CHARACTERISTICS OF UVEITIS IN BEHCET’S SYNDROME; A RETROSPECTIVE ANALYSIS OF 109 PATIENTS
Authors: R. Yildirim, M. Dinler, N. S. Yasar Bilge, T. Kaşifoğlu
Journal: Annals of the Rheumatic Diseases (2022)

Background Uveitis is still an important cause of morbidity leading to vision loss in Behcet’s syndrome (BS). Objectives Our aim in this study was to retrospectively evaluate characteristics of uveitis, long term complications, and its association with the other components of BS. Methods 800 patients with BS diagnosis according to International Study Group for Behcet’s Disease (ISG) criterias in our center were screened and among those, data of 109 patients with BS-related uveitis were included in this study. Results The overall prevalence of uveitis was found 13% among all BS population. Majority of BS-related uveitis were male (65,1%/34,9%). Mean age for BS diagnosis and onset of uveitis were found 28 ± 8,48 and 27 ± 8,42 years. In this group, uveitis developed before BS diagnosis in 33% of patients, whereas 44% were diagnosed at onset of uveitis.The frequency of this population was estimated 6% among all BS patients,. Characteristics of uveitis were as following; unilateral (45/99), bilateral (54/99), anterior (12), posterior (30), panuveitis (30), retinal vasculitis (9) and not defined (9). 25 patients experienced only one attack, whereas more than one attack was seen in 45 patients during follow up. 74 patients whose complications data was available, cataract, maculopathy, glaucoma, and optic atrophy developed in 10, 7, 6 and 3 patients, respectively. Vision loss was seen in 8 patients as partial, in 28 as total (Table 1). Table 1. Characteristics of uveitis, complications and other components of BS patients Male/female, (n), (%) 71/28 (%65,1/%34,9) Age at diagnosis, years (Mean± SD) 28 ±8,48 Age at uveitis, years (Mean± SD) 27 ±8,42 Uveitis-Behcet’s diagnosis relationship, (n) 109 -Before, (n), (%) 36 (%33) -At the time of, (n), (%) 48 (%44) -After, (n), (%) 25 (%23) Characteristics of uveitis, (n) 99/109 -Unilateral/Bilateral 45/54 -Anterior 12 -Posterior 30 -Panuveitis 30 -Retinal vasculitis 9 Complications, (n) 26/74 -Maculopathy 7 -Glaucoma 6 -Cataract 10 -Optic atrophy 5 -Vision loss (partial/total) 8/28 BS; Behcet’s syndrome Conclusion Male gender and onset at young age are important risk factors for uveitis development. Uveitis is seen as a critical component for diagnosis. Complications, despite declining in the era of biologics use, are still a major concern. Retrospective design and missing data are limitations of this study. References [1]Saadouli D, Lahmar A, Ben Mansour K, El Afrit N, Yahyaoui S, El Afrit MA. Les manifestations oculaires au cours de la maladie de Behçet [Ocular manifestations of Behçet’s disease]. J Fr Ophtalmol. 2021;44(2):196-202. Disclosure of Interests None declared
AB0741 Lung functions in idiopathic inflammatory myopathies patients with interstitial lung disease during ≥ 3 year of follow-up.
Authors: A. Khelkovskaia-Sergeeva, L. Garzanova, M. Starovoytova, O. Desinova, L. P. Ananyeva, O. Koneva
Journal: Annals of the Rheumatic Diseases (2022)

Background Interstitial lung disease (ILD) is the most common internal organ manifestation of idiopathic inflammatory myopathies (IIM) that can severely affect the course of the disease. Objectives To describe lung functions in IIM patients with ILD during ≥ 3 year of follow-up. Methods Our prospective study included 44 pts with IIM fulfilling Bohan and Peter criteria and having ILD. The mean follow-up period was 46.2±11.2 months. The mean age was 52.3±11.7 years, 34 (77.3%) pts were female. The median disease duration was 1.125 [0.16-18] years, 24 (54%) of pts were positive for a-Jо-1 antibody. All pts had the standard examination including anti-Jo-1 antibodies (anti-Jo-1) assay; forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLCO) evaluation as well as high-resolution computed tomography (HRCT) scanning of the chest were performed at baseline, and 36 and more months. Results 61% with antisynthetase syndrome, 17% dermatomyositis (DM), 5% amyopathic DM, 15% with overlap myositis and 2 % with necrotizing myopathy were included. 70% patients had nonspecific interstitial pneumonia, 23% organizing pneumonia (OP) and 7% OP, transformed to diffuse alveolar damage. All pts received prednisolone at a dose of 11.8±4.1 mg/day, immunosupressants at inclusion received 75% pts: cyclophosphamide 54%, mycophenolate mofetil 16.9% and combination 4.54%; Rituximab was administered in case of intolerance or inadequate response to GC and other immunosuppressive drugs in 37 pts (84%)(1-8 courses). 7 patients died, ILD progression was the cause of death in 4 cases Table 1. Changes of the main parameters at the baseline and in 3 years parameters pts baseline in ≥ 3 years р a-Jо-1 23 177.2 ±41.7 90.5±76.7 0.000003 FVC 37 83.3±21.7 96.7±21 0.0001 DLCO % 37 52.4±14.9 60.8±17,3 0.001 Prednison, mg/day 37 23.04±12.8 5.9±2.3 0,000000001 Conclusion Active immunosuppressive therapy improves lung function in IIM patients. However, some forms of ILD have a fatal course. Disclosure of Interests None declared
POS0444 PROFILING OF CIRCULATING miRNAs IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS
Authors: J. Baloun, A. Pekacova, H. Mann, J. Vencovský, K. Pavelka, L. Šenolt
Journal: Annals of the Rheumatic Diseases (2022)

Background Biologic (b-) and targeted synthetic (ts-) disease-modifying antirheumatic drugs (DMARDs) have brought significant progress in the treatment of rheumatoid arthritis (RA), but a significant proportion of RA patients still remain symptomatic despite treatment according to current recommendations. These patients have recently been defined as “difficult-to-treat (D2T)” RA (1). There is evidence that miRNA expression may play a role in the diagnosis and therapy of RA (2). Objectives In a retrospective study, we analyzed patients’ blood samples prior to b-/ts-DMARD treatment and profiled circulating miRNAs to predict the development of D2T-RA. Methods A total of 36 patients fulfilling the EULAR definition of D2T-RA (1) (mean age 59.1±10.7 yrs, 78% females), 36 patients with RA in sustained clinical remission on b-/ts-DMARDs at two consecutive examinations 12 wks apart (mean age 66.3±9.6 yrs, 78% females), and 36 healthy controls (mean age 61.1±7.7 yrs, 68% females) were included in the study. Blood samples were collected before initiation of b-/ts-DMARD. We profiled circulating miRNAs using the sequencing approach and differential expression analysis was performed using DESeq2 algorithm. Results The massive parallel sequencing of circulating miRNAs detected 814 quantifiable miRNAs and DESeq2 algorithm revealed 35 miRNAs with different concentrations in patients who developed D2T-RA compared to patients with RA who achieved sustained remission or healthy controls. Out of these miRNAs, miR-16-5p (1.5x) and miR-451a (2.1x) were downregulated and miR-126-3p (1.4x) was upregulated in D2T RA patients compared to controls. In addition, miR-101-3p (1.5x) was downregulated in D2T RA compared to RA patients. Except for miR-101-3p, these miRNAS have been previously associated with RA and might predict development of D2T disease prior to initiation of b-/ts-DMARD therapy. Conclusion We found four miRNAs as potential biomarkers differentiating patients who are at risk to develop difficult-to-treat disease compared to patients who have a chance of sustained remission even before initiation of biological or targeted synthetic DMARDs. Further studies with larger sample size are needed to validated these data. References [1]Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. [2]Filková M, Jüngel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs. 2012 Jun 1;26(3):131-41. Acknowledgements This work was supported by the project SVV 260 523, BBMRI-CZ LM2018125, and a project of the MHCR for conceptual research development No. 023728. Disclosure of Interests None declared.
AB0487 SJÖGREN SYNDROME: DESCRIPTIVE AND COMPARATIVE STUDY OF PRIMITIVE AND ASSOCIATED FORMS
Authors: S. Skhiri, A. Baya Chatti, W. Ben Yahia, A. Atig, N. Ghannouchi
Journal: Annals of the Rheumatic Diseases (2022)

Background Sjögren syndrome (SS) is an autoimmune disease (AID) characterized by a dysfunction of the exocrine glands (mainly salivary and tear glands). It is responsible for xerostomia and xerophtalmia as well as systemic manifestations that may affect multiple organs. This syndrome comes in two forms: primary when it is isolated (pSS) and associated (aSS) when it is in association with another AID whether it is specific of organs or not. These two entities have different particularities, requiring explorations and adapted treatments. Few studies have taken interest in determining them. Objectives The objective of this study was to compare the various clinical and evolutionary manifestations of these two forms. Methods We conducted a retrospective analytical study over a period of 33 years. All patients with SS based on ACR 2012 and/or ACR/EULAR classification criteria were included. Epidemiological, clinical, para-clinical, therapeutic and disease course characteristics in both groups (pSS and aSS) were described and compared. Results One hundred and forty-five patients were included. Sixty-three (43.4%) had pSS and 82 (56.5%) had aSS. The pSS group consisted of 58 women (92%) and five men (8%) with a mean age at diagnosis of 51.9 ±15.3 years. Seventy-eight women (95%) and four men (5%) with a mean age at diagnosis of 45.4±16.2 years had a SS. The most common AADs associated with the latter were SLE (39%) and RA (18.3%). The comparison of the two groups concluded that the mean age at the time of diagnosis was significantly higher in patients with pSS (p= 0.01). Glandular involvement was almost constant in both groups. Joint involvement, skin involvement and Raynaud’s syndrome were significantly more common in the aSS group (p&lt; 0.01; &lt; 0.001 and 0.02 respectively). Central neurological involvement was significantly more common in the pSS group (p=0.04). The other clinical manifestations were comparable in both groups. Comparison of biological abnormalities between pSS and aSS showed a statistically higher frequency of leukopenia (p=0.04), lymphopenia (p &lt;0.001), Antinuclear antibodies (p=0.001), anti SSA antibodies (p=0.003), rheumatoid factor (p &lt; 0.001) and anti CCP antibodies (p&lt;0.001) in aSS. Synthetic antimalarial drugs, corticosteroids and immunosuppressive treatment were significantly more prescribed for aSS (p= 0.003, p &lt; 0.001 and p=0.02 respectively). After a mean of follow up of 3 ±4.5 years for the pSS and 4 ±4.5 years for the aSS. No cases of lymphoma were observed in both groups. Conclusion Differentiating between pSS and aSS is crucial in order to establish an early diagnosis and ensure adequate management and a better prognosis. Larger-scale studies appear to be needed to optimize management. Disclosure of Interests None declared